JBIO Cash-Secured Put Strategy
JBIO (Jade Biosciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
JBIO (Jade Biosciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $817.9M, a beta of 1.52 versus the broader market, a 52-week range of 6.565-28, average daily share volume of 548K, a public-listing history dating back to 2025, approximately 50 full-time employees. These structural characteristics shape how JBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.52 indicates JBIO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. JBIO pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a cash-secured put on JBIO?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current JBIO snapshot
As of May 15, 2026, spot at $23.54, ATM IV 152.80%, IV rank 24.68%, expected move 43.81%. The cash-secured put on JBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this cash-secured put structure on JBIO specifically: JBIO IV at 152.80% is on the cheap side of its 1-year range, which means a premium-selling JBIO cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 43.81% (roughly $10.31 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated JBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on JBIO should anchor to the underlying notional of $23.54 per share and to the trader's directional view on JBIO stock.
JBIO cash-secured put setup
The JBIO cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With JBIO near $23.54, the first option leg uses a $22.36 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed JBIO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 JBIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $22.36 | N/A |
JBIO cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
JBIO cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on JBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on JBIO
Cash-secured puts on JBIO earn premium while a trader waits to acquire JBIO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning JBIO.
JBIO thesis for this cash-secured put
The market-implied 1-standard-deviation range for JBIO extends from approximately $13.23 on the downside to $33.85 on the upside. A JBIO cash-secured put lets a trader earn premium while waiting to acquire JBIO at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current JBIO IV rank near 24.68% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on JBIO at 152.80%. As a Healthcare name, JBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to JBIO-specific events.
JBIO cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. JBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move JBIO alongside the broader basket even when JBIO-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on JBIO carry tail risk when realized volatility exceeds the implied move; review historical JBIO earnings reactions and macro stress periods before sizing. Always rebuild the position from current JBIO chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on JBIO?
- A cash-secured put on JBIO is the cash-secured put strategy applied to JBIO (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With JBIO stock trading near $23.54, the strikes shown on this page are snapped to the nearest listed JBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are JBIO cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the JBIO cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 152.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a JBIO cash-secured put?
- The breakeven for the JBIO cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current JBIO market-implied 1-standard-deviation expected move is approximately 43.81%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on JBIO?
- Cash-secured puts on JBIO earn premium while a trader waits to acquire JBIO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning JBIO.
- How does current JBIO implied volatility affect this cash-secured put?
- JBIO ATM IV is at 152.80% with IV rank near 24.68%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.